Oppenheimer upgrades Freshpet stock rating on growth outlook

Oppenheimer upgraded Freshpet to Outperform with an $80.00 price target; the stock trades at $63.17, down 17.5% over the past week after a >10% pullback on March 17, 2026. Analysts highlight an attractive valuation (PEG 0.12) and confidence in management to stabilize high-single-digit top-line growth, with competing price targets from Piper Sandler $87, Baird $90, Stifel $84, DA Davidson $98 and BofA $80 (Neutral). Firms also note potential M&A optionality as major pet players adjust portfolios, while flagging the risk of Costco’s private-label competition.

Analysis

Costco’s Kirkland private-label push is a credible headline risk, but its net effect is likely heterogeneous: it will take share fastest in price-sensitive, shelf-stable subcategories while encountering friction in refrigerated, fresh-format SKUs that require in-store refrigeration investment and tighter supply-chain integration. That creates a two-speed outcome where national fresher brands lose share at the margin but see acceleration in absolute category demand as consumers trial refrigerated fresh options they previously avoided.

Second-order winners include cold‑chain logistics providers, co-packers and MAP/PET packaging suppliers — any vendor that lowers per-unit cold storage costs will raise the economic moat for premium fresh players by reducing price elasticity. Near-term catalysts to watch are Costco sell‑through data (weekly velocity by SKU), Freshpet’s trade/spend cadence and gross-margin trajectory: a sustained margin stabilization without outsized trade spend would materially de-risk the consensus scenario within 3–9 months.

Key tail risks are swift private‑label conversion in club channels (which would force elevated promotional intensity and structurally compress margins) and a category recall or food‑safety incident that could reset valuation multiples for all fresh pet brands. Conversely, M&A optionality is under‑priced: a strategic buyer with national refrigerated distribution could pay a control premium, compressing time-to-recovery for current holders. Overall the market appears to be pricing a low‑probability downside scenario as if it were certain; the asymmetry favors disciplined exposure with defined downside protection over outright binary speculation.

Key Decisions for Investors

• Long FRPT via a 6–9 month call-debit spread (buy near‑the‑money call, sell 20–30% OTM call) sized to 2–4% of portfolio to capture re‑rating/ takeout optionality; target 40–60% upside, max loss = premium paid. Enter on short-term weakness or on confirmation of stabilized gross margins for two consecutive quarters.
• Express conviction with a pair: long FRPT equity (1x) financed by a small short COST position (0.2–0.3x dollar notional) for 3–6 months to hedge broad consumer/club channel exposure. Limit downside with a hard stop at 12–15% on the FRPT leg; expected asymmetric payoff if share-loss fears prove overstated.
• Buy short‑dated FRPT protective puts (2–3 month) to cover existing long exposure ahead of key sell‑through/earnings prints; cost of puts should be budgeted as insurance — trade-off: preserves upside optionality while limiting headline-driven drawdowns to pre-set tolerance.
• If conviction rises from observed share stabilization and improved sell-through at club channels, transition to a buy-and-write: buy FRPT and sell 6–9 month OTM covered calls to monetize time value while retaining upside to a likely buyout/ re‑rating event.